Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials

References

• Ferrari MD, Roon KI, Lipton RB, et al. Oral triptans (serotonin 5-HT1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001;358:1668–75
   PubMed Web of Science ®Google Scholar
• Adelman JU, Lipton RB, Ferrari MD, et al. Comparison of rizatriptan and other triptans on stringent measures of efficacy. Neurology 2001;57:1377–83
   PubMed Web of Science ®Google Scholar
• Oldman AD, Smith LA, McQuay HJ, et al. Pharmacological treatments for acute migraine: quantitative systematic review. Pain 2002;97:247–57
   PubMed Web of Science ®Google Scholar
• Belsey J. Reconciling effectiveness and tolerability in oral triptan therapy: a quantitative approach to decision making in migraine management. J Clin Res 2001;4:105–25
   Google Scholar
• Adelman JU, Belsey J. Meta-analysis of oral triptan therapy for migraine: number needed to treat and relative cost to achieve relief within 2 h. J Managed Care Pharm 2003;9:45–52
   Google Scholar
• Belsey JD. The clinical and financial impact of oral triptans – an updated meta-analysis. J Med Econ 2002;5:79–89
   Google Scholar
• Pilgrim AJ. Methodology of clinical trials of sumatriptan in migraine and cluster headache. Eur Neurol 1991;31:295–9
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Bousser MG, Solomon S. Guidelines for controlled trials of drugs in migraine, 1st edn, 1991, pp.111–33
   Google Scholar
• Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomised clinical trials: is blinding necessary? Controlled Clin Trials 1996;17:1–12
   PubMedGoogle Scholar
• Sheftell FD, Fox AW. Acute migraine treatment outcome measures: a clinician’s view. Cephalalgia 2000;20\(suppl 2):14–24
   Google Scholar
• Cook RJ, Sackett D. The number needed to treat: a clinically useful measure of treatment effect. Br Med J 1995;310:452–4
   PubMed Web of Science ®Google Scholar
• Dahlof C, Tfelt-Hansen P, Massiou H, et al. Dose finding, placebo-controlled study of oral almotriptan in the acute treatment of migraine. Neurology 2001;57:1811–7
   PubMed Web of Science ®Google Scholar
• Pascual J, Falk RM, Piessens F, et al. Consistent efficacy and tolerability of almotriptan in the acute treatment of multiple migraine attacks: results of a large, randomised, double-blind, placebo-controlled study. Cephalalgia 2000;20:588–96
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Massiou H, Lainez JM, et al. Almotriptan is an effective and well-tolerated treatment for migraine-pain: results of a randomised, double-blind, placebo-controlled trial. Cephalalgia 2002;22:453–61
   PubMed Web of Science ®Google Scholar
• Sheftell F, Ryan R, Pitman V, et al. Efficacy, safety and tolerability of oral eletriptan for treatment of acute migraine: a multicentre, double-blind, placebo-controlled study conducted in the United States. Headache 2003;43:202–13
   PubMed Web of Science ®Google Scholar
• Eletriptan Steering Committee in Japan. Efficacy and safety of eletriptan 20 mg, 40 mg and 80 mg in Japanese migraineurs. Cephalalgia 2002;22:416–23
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Ferrari MD, Olesen J, et al. Eletriptan in acute migraine: a double-blind, placebo-controlled comparison to sumatriptan. Neurology 2000;54:156–63
   PubMed Web of Science ®Google Scholar
• Farkkila M, Olesen J, Dahlof C, et al. Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan. Cephalalgia 2003;23:463–71
   PubMed Web of Science ®Google Scholar
• Diener HC, Jansen JP, Reches A, et al. Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison. Eur Neurol. 2002;47:99–107
   PubMed Web of Science ®Google Scholar
• Stark R, Dahlof C, Haughie S, et al. Efficacy, safety and tolerability of oral eletriptan in the acute treatment of migraine: Results of a phase III, multicentre, placebo-controlled study across three attacks. Cephalalgia 2002;22:23–32
   PubMed Web of Science ®Google Scholar
• Mathew NT, Schoenen J, Winner P, et al. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache 2003;43:214–22
   PubMed Web of Science ®Google Scholar
• Goldstein J, Keywood C. Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache 2002;42:41–8
   PubMed Web of Science ®Google Scholar
• Ryan R, Geraud G, Goldstein J, et al. Clinical efficacy of frovatriptan: placebo-controlled studies. Headache 2002;42\(suppl 2):S84–92
   Google Scholar
• Bomhof M, Paz J, Legg N, et al. Comparison of rizatriptan 10 mg vs. naratriptan 2.5 mg in migraine. Eur Neurol 1999;42:173–9
   PubMed Web of Science ®Google Scholar
• Teall J, Tuchman M, Cutler N, et al. Rizatriptan (MAXALT) for the acute treatment of migraine and migraine recurrence. A placebo-controlled, outpatient study. Headache 1998;38:281–7
   Google Scholar
• Gijsman H, Kramer MS, Sargent J, et al. Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine. Cephalalgia 1997;17:647–51
   PubMed Web of Science ®Google Scholar
• Ahrens SP, Farmer MV, Williams DL, et al. Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Cephalalgia 1999;19:525–30
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Teall J, Rodriguez F, et al. Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Headache 1998;38:748–55
   Google Scholar
• Winner P, Lewis D, Visser H, et al. Rizatriptan 5mg for the acute treatment of migraine in adolescents: a randomised, double-blind, placebo-controlled study. Headache 2002;42:49–55
   PubMed Web of Science ®Google Scholar
• Visser WH, Terwindt GM, Reines SA, et al. Rizatriptan vs sumatriptan in the acute treatment of migraine. A placebo-controlled, dose-ranging study. Arch Neurol 1996;53:1132–7
   PubMed Web of Science ®Google Scholar
• Kramer MS, Matzura-Wolfe D, Polis A, et al. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks. Neurology 1998;51:773–81
   PubMed Web of Science ®Google Scholar
• Pascual J, Vega P, Diener H-C, et al. Comparison of rizatriptan 10 mg vs. zolmitriptan 2.5 mg in the acute treatment of migraine. Cephalalgia 2000;20: 455–61
   Google Scholar
• Savani N, Brautaset NJ, Reunanen M, et al. A double-blind placebo-controlled study assessing the efficacy and tolerability of 50mg sumatriptan tablets in the acute treatment of migraine. Int J Clin Pract 1999;105(Suppl):7–15
   Google Scholar
• Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan. Headache 1998;38:184–90
   PubMed Web of Science ®Google Scholar
• Cutler N, Mushet GR, Davis R, et al. Oral sumatriptan for the acute treatment of migraine: evaluation of three dosage strengths. Neurology 1995;45:S5–S9
   Web of Science ®Google Scholar
• Geraud G, Oleson F, Pfaffenrath V, et al. Comparison of the efficacy of zolmitriptan and sumatriptan: issues in migraine trial design. Cephalalgia 2000;20:30–8
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Henry P, Mulder LJ, et al. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1995;346:923–6
   Google Scholar
• Myllyla VV, Havanka H, Herrala L, et al. Tolfenamic acid rapid release versus sumatriptan in the acute treatment of migraine: comparable effect in a double-blind, randomized, controlled, parallel-group study. Headache 1998;38:201–7
   PubMed Web of Science ®Google Scholar
• Nappi G, Sicuteri F, Byrne M, et al. Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994;241:138–44
   PubMed Web of Science ®Google Scholar
• Oral Sumatriptan International Multiple-Dose Study Group. Evaluation of a multiple-dose regimen of oral sumatriptan for the acute treatment of migraine. Eur Neurol 1991;31:306–13
   PubMed Web of Science ®Google Scholar
• Rapoport AM, Ramadan NM, Adelman JU, et al. Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine: a multicentre, double-blind, placebo-controlled, dose range-finding study. Neurology 1997;49:1210–8
   PubMed Web of Science ®Google Scholar
• Solomon GD, Cady RK, Klapper JA, et al. Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997;49:1219–25
   Google Scholar
• Sakai F, Iwata M, Tashiro K, et al. Zolmitriptan is effective and well tolerated in Japanese patients with migraine: a dose–response study. Cephalalgia 2002;22:376–83
   PubMed Web of Science ®Google Scholar
• Dowson AJ, MacGregor EA, Purdy RA, et al. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia 2002;22:101–6
   PubMed Web of Science ®Google Scholar
• Visser WH, Klein KB, Cox RC, et al. 311C90, a new central and peripherally acting 5-HT1D receptor agonist in the acute oral treatment of migraine: a double-blind, placebo-controlled, dose-range finding study. Neurology 1996;46: 522–6
   PubMed Web of Science ®Google Scholar
• Dahlof C, Diener H-C, Goadsby PJ, et al. Zolmitriptan, a 5-HT1B/1D receptor agonist for the acute oral treatment of migraine: a multicentre, dose-range finding study. Eur J Neurol 1998;5: 535–43
   Google Scholar
• Caro G, Getsios D, Caro JJ, et al. Sumatriptan: economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis. Cephalalgia 2001;21:12–9
   PubMed Web of Science ®Google Scholar
• Caro JJ, Getsios D, Raggio G, et al. Treatment of migraine in Canada with naratriptan: a cost-effectiveness analysis. Headache 2001;41:456–64
   PubMed Web of Science ®Google Scholar
• Lofland JH, Kim SS, Batenhorst AS, et al. Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine. Mayo Clin.Proc. 2001;76:1093–101
   PubMed Web of Science ®Google Scholar
• Schulman EA, Cady RK, Henry D, et al. Effectiveness of sumatriptan in reducing productivity loss due to migraine: results of a randomized, double-blind, placebo-controlled clinical trial. Mayo Clin Proc 2000;75:782–9
   PubMed Web of Science ®Google Scholar
• Biddle AK, Shih YC, Kwong WJ. Cost-benefit analysis of sumatriptan tablets versus usual therapy for treatment of migraine. Pharmacotherapy 2000;20:1356–64
   Google Scholar
• Sculpher M, Millson D, Meddis D, Poole L. Cost-effectiveness analysis of stratified versus stepped care strategies for acute treatment of migraine: The Disability in Strategies for Care (DISC) Study. Pharmacoeconomics 2002;20:91–100
   PubMed Web of Science ®Google Scholar
• Maizels M, Saenz V, Wirjo J. Impact of a group-based model of disease management for headache. Headache 2003;43:621–7
   PubMed Web of Science ®Google Scholar
• Wells N, Hettiarachchi J, Drummond M, et al. A cost-effectiveness analysis of eletriptan 40 and 80 mg versus sumatriptan 50 and 100 mg in the acute treatment of migraine. Value Health 2003;6:438–47
   PubMed Web of Science ®Google Scholar
• Evans KW, Boan JA, Evans JL, Shuaib A. Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine. Pharmacoeconomics 1997;12:565–77
   PubMed Web of Science ®Google Scholar
• Reeder CE, Steadman S, Goldfarb SD. Economic comparison of oral triptans for management of acute migraine: implications for managed care. Am J Manag Care 2002;8:S80–S84
   Google Scholar
• Gobel H, Heinze A, Heinze-Kuhn K, et al. Efficacy and tolerability of rizatriptan 10 mg in migraine: experience with 70,527 patient episodes. Headache 2001;41: 264–70
   Google Scholar
• Leira R, Dualde E, del Barrio H, et al. Almotriptan versus rizatriptan in patients with migraine in Spain. Headache 2003;43:734–41
   PubMed Web of Science ®Google Scholar